Fibrotech, Shire deal

Shire will acquire fibrosis play Fibrotech for $75 million up front, plus undisclosed milestones. Fibrotech's FT011 is in a Phase Ib trial to treat diabetic nephropathy. Next year, Shire plans to sta...